Chicago Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

Chicago Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-414,500	Closed	-$14.3M	–	25
2020 Q3	$14.3M	Buy	+414,500	New	+$8.83M	13.67%	4

Chicago Capital Management's AIMT Position: Q4 2020 in Review

Chicago Capital Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 414,500 shares — an estimated $14.3M sold.

Chicago Capital Management first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $14.3M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Chicago Capital Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Chicago Capital Management sold 414,500 Aimmune Therapeutics shares in Q4 2020, an estimated $14.3M.
Chicago Capital Management first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
Chicago Capital Management's Aimmune Therapeutics position peaked at $14.3M in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Chicago Capital Management's 13F filing for Q4 2020, filed 10 Feb 2021.